Evercore ISI analyst Gavin Clark-Gartner lowered the firm’s price target on AbbVie (ABBV) to $228 from $232 and keeps an Outperform rating on the shares. Despite Tremfya clearly taking share, 2026 guidance/consensus still look beatable, same with 2027, the analyst tells investors in a research note. The firm also said that it is “worth noting” that the buyside has been above consensus for a while, and the margin beats look smaller. Evercore added that the real issue the stock is reflecting is the 2028+ growth, especially as more new entrants come online.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Clear Street says AbbVie move further validates Oruka Therapeutics’ strategy
- Midday Fly By: AMD falls despite Q4 beat, Uber reports mixed results
- AbbVie says ‘plenty of capacity’ to invest in internal and external innovation
- AbbVie sees FY26 adjusted gross margin ‘above 84% of sales’
- AbbVie sees Q1 adjusted EPS $2.97-$3.01, consensus $3.10